The collaboration brings together Ariadne, Cellecta, and the Roswell Park Cancer Institute to develop "a better understanding of the mechanisms of prostate cancer that result in novel targets and biomarkers."
In a study using a well-defined set of 30 prostate cancer plasma samples and 14 male controls, researchers detected the biomarker in three of the 14 control samples and in 27 of the 30 prostate cancer samples.
Canada's research institutions should launch a new prostate cancer sequencing project within the International Cancer Genome Consortium, and promote the value of its data to Canadian researchers, a 22-member alliance recommended today in its Pan-Canadian Cancer Research Strategy.
The results offer the prospect for improved detection and measurement of low-concentration proteins – a development that has potentially broad applications in protein biomarker research, diagnostics, and drug development, David Duffy, senior director of platform research at Quanterix, told ProteoMonitor.
A University of Michigan team identified gene fusions in the RAF kinase pathway in prostate cancer, gastric cancer, and melanoma. The researchers said the pathway could potentially be targeted by drugs that are currently in development.
Data presented by Myriad at AACR support the "hypothesis that PTEN status predicts outcome after radical prostatectomy, and suggest further, that PTEN may be a clinically important molecular marker for defining aggressive prostate cancer."
The protocol may better enable researchers in other labs to conduct microRNA biomarker research, and is an incremental step toward developing a blood-based cancer detection method based on circulating microRNAs.